Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1855]

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich

Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )

Visugromab plus nivolumab significantly increases pathologic response in muscle...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

ESMO 2025: Bladder cancer highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ESMO 2025: Bladder cancer highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ESMO 2025: Prostate highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ESMO 2025: Prostate highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ESMO 2025: Renal highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ESMO 2025: Renal highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR...

Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC ( Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China )

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients...

Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors ( Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain )

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher...

Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity ( Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada )

Perioperative enfortumab vedotin plus pembro improves survival and pCR in...

Prof Christof Vulsteke - Maria Middelares General Hospital, Ghent, Belgium

Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBC ( Prof Christof Vulsteke - Maria Middelares General Hospital, Ghent, Belgium )

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine...

Dr Charles E. Geyer - University of Pittsburgh School of Medicine, Pittsburgh...

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer ( Dr Charles E. Geyer - University of Pittsburgh School of Medicine, Pittsburgh, USA )

Avelumab maintenance after reduced chemotherapy cycles improves QoL without...

Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC ( Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain )

More from ecancer